文献速递眼整形与眼眶神经眼科

3项临床试验中接受替妥木单抗治疗的甲状腺眼病患者的血糖趋势

Glycemic Trends in Patients with Thyroid Eye Disease Treated with Teprotumumab in 3 Clinical Trials.
PubMed 文献 · Ophthalmology · 2024-01-20

该研究汇总了3项临床试验中接受替妥木单抗或安慰剂治疗的甲状腺眼病患者的血糖数据,分析高血糖事件发生率、严重程度及血糖波动情况。结果显示,基线血糖正常者治疗期间严重血糖波动不常见;基线糖尿病前期/糖尿病患者中多数高血糖事件可通过药物控制,后续给药未见高血糖进展或发生率增加。

要点

  • 2/3期研究中,替妥木单抗组8例患者发生9次高血糖事件,平均HbA1c从基线至第24周升高0.22%至5.8%。
  • 研究结束时,替妥木单抗组78%(59/76)和安慰剂组87%(67/77)患者血糖正常。
  • 基线糖尿病前期患者中,第24周替妥木单抗组29%(2/7)和安慰剂组14%(1/7)出现糖尿病表现。

核心结论

  • 基线血糖正常的甲状腺眼病患者接受替妥木单抗治疗时严重血糖波动不常见。
  • 基线糖尿病控制稳定或糖耐量受损的患者,若进行基线筛查、定期血糖监测并及时治疗高血糖,可安全接受替妥木单抗治疗。

研究设计与样本

  • 汇总3项临床试验的血糖数据进行分析:2期和3期(OPTIC)对照试验中84例替妥木单抗治疗和86例安慰剂治疗的活動性甲状腺眼病患者,以及OPTIC扩展试验(OPTIC-X)中51例替妥木单抗治疗患者。
  • 替妥木单抗通过8次静脉输注给药,历时21周。

主要发现

  • 2期和3期研究中,替妥木单抗组8例患者发生9次高血糖事件;平均HbA1c从基线至第24周升高0.22%至5.8%(范围5.0%-7.9%),安慰剂组升高0.04%至5.6%(范围4.6%-8.1%)。
  • 研究结束时,替妥木单抗组78%(59/76)和安慰剂组87%(67/77)患者血糖正常;血糖正常维持率分别为84%(57/68)和93%(64/69)。
  • 基线糖尿病前期患者中,两组均有43%(3/7)维持糖尿病前期,第24周替妥木单抗组29%(2/7)和安慰剂组14%(1/7)出现糖尿病表现。
  • OPTIC-X患者无论初次治疗还是再次接受替妥木单抗,空腹血糖和HbA1c均呈升高趋势;空腹血糖常在2或3次输注后升高,此后趋于稳定。
  • 大多数高血糖事件发生于基线糖尿病前期/糖尿病患者,且可通过药物控制;未发现后续给药导致高血糖进展或发生率增加的证据。

临床怎么用

  • 作者结论认为,基线血糖正常的甲状腺眼病患者严重血糖波动不常见。
  • 作者结论认为,基线糖尿病控制稳定或糖耐量受损的患者,若进行基线筛查、定期血糖监测并及时治疗高血糖,可安全接受替妥木单抗治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Assess incidence, severity, and glucose excursion outcomes in thyroid eye disease (TED) patients receiving the insulin-like growth factor-1 receptor inhibitor teprotumumab from 3 clinical trials. DESIGN: Analysis of pooled glycemic data over time. PARTICIPANTS: Eighty-four teprotumumab- and 86 placebo-treated active TED patients from the phase 2 and phase 3 (OPTIC) controlled clinical trials and 51 teprotumumab-treated patients from the OPTIC extension (OPTIC-X) trial. METHODS: Eight intravenous infusions were given over 21 weeks. Phase 2 serum glucose was measured at weeks 1, 4, 15, and 21, with fasting measurements at weeks 1 and 4. Serum glucose was measured at each study visit in OPTIC and OPTIC-X, with fasting measurements at weeks 1 and 4 (in patients without diabetes) or all visits (in patients with diabetes). In all studies, hemoglobin A1c (HbA1c) was measured at baseline, 12, and 24 weeks plus weeks 36 and 48 in OPTIC-X. MAIN OUTCOME MEASURES: Serum glucose and HbA1c. RESULTS: In the phase 2 and 3 studies, 9 hyperglycemic episodes occurred in 8 teprotumumab patients; mean HbA1c level increased 0.22% from baseline to week 24 (to 5.8%; range, 5.0%-7.9%) versus 0.04% in patients receiving the placebo (to 5.6%; range, 4.6%-8.1%). At study end, 78% (59/76) of teprotumumab patients and 87% (67/77) of patients receiving placebo had normoglycemic findings. Normoglycemia was maintained in 84% (57/68) of patients receiving teprotumumab and 93% (64/69) of patients receiving placebo. Among baseline prediabetic patients, 43% (3/7) remained prediabetic in both groups, and 29% (2/7) of teprotumumab patients and 14% (1/7) of patients receiving placebo had diabetic findings at week 24. OPTIC-X patients trended toward increased fasting glucose and HbA1c whether initially treated or retreated with teprotumumab. Fasting glucose commonly rose after 2 or 3 infusions and stabilized thereafter. Most hyperglycemic incidents occurred in patients with baseline prediabetes/diabetes but were controlled with medication. No evidence was found for progression or increased incidence of hyperglycemia with subsequent doses. CONCLUSIONS: Serious glycemic excursions are uncommon in patients with normoglycemia before teprotumumab therapy. Patients with controlled diabetes or impaired glucose tolerance can be treated safely if baseline screening, regular monitoring of glycemic control, and timely treatment of hyperglycemia are practiced. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Smith TJ, Cavida D, Hsu K, et al. Glycemic Trends in Patients with Thyroid Eye Disease Treated with Teprotumumab in 3 Clinical Trials. Ophthalmology. 2024. PMID: 38253291. doi:10.1016/j.ophtha.2024.01.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。